Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC(R), a cell-free hydrogel implant designed to repair knee cartilage damage through a single approximately 10-minute procedure, positioning the company to address a major unmet need in orthopedic medicine. While roughly 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, no approved off-the-shelf regenerative solution capable of restoring hyaline-like cartilage currently exists in the U.S. market. Unlike traditional microfracture procedures or complex cell-based therapies that often require multiple surgeries and lengthy preparation, GelrinC(R) is designed as a ready-to-use implant that supports native cartilage regeneration over time. The product has already received CE Mark approval in Europe and is advancing through a pivotal U.S. FDA trial that is now more than 50% enrolled. Regentis is also preparing for potential commercialization, highlighted by a newly patented solvent-free manufacturing process that increased production yield by 400%, alongside ongoing efforts to build physician adoption infrastructure across Europe.
At a glance
- Company
- Regentis Biomaterials Ltd.
- Ticker
- NYSE American: RGNT
- Announcement
- Product
Key figures
- Annual U.S. arthroscopic knee procedures involving cartilage damage
- roughly 472,500
- Procedure duration
- approximately 10-minute
- Pivotal U.S. FDA trial enrollment
- more than 50%
- Production yield increase
- 400%
Products and programs
To view the full article, visit https://ibn.fm/TrCv1
About Regentis Biomaterials
Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R), is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
In brief
Regentis Biomaterials says it is developing GelrinC, a cell-free hydrogel implant intended to repair knee cartilage in a single procedure lasting about 10 minutes. The company cites approximately 472,500 U.S. arthroscopic knee procedures involving cartilage damage each year and says no approved, off-the-shelf regenerative option to restore hyaline-like cartilage is currently available in the U.S. GelrinC has received CE Mark approval in Europe, and its pivotal U.S. FDA trial is more than 50% enrolled, according to the release. Regentis also reports a newly patented solvent-free manufacturing process that increased production yield by 400%. The company says it is preparing for potential commercialization and developing physician adoption infrastructure in Europe.
Key takeaways
- GelrinC is a cell-free hydrogel implant designed for knee cartilage repair in a single procedure.
- The company says its pivotal U.S. FDA trial is more than 50% enrolled.
- GelrinC has received CE Mark approval in Europe, according to Regentis.
- Regentis reports a 400% production-yield increase from a patented solvent-free manufacturing process.
